Stay updated on Anti-CD38 Antibody Trial in CD38+ Malignancies
Sign up to get notified when there's something new on the Anti-CD38 Antibody Trial in CD38+ Malignancies page.

Latest updates to the Anti-CD38 Antibody Trial in CD38+ Malignancies page
- Check7 days agoChange DetectedThe new screenshot shows the same study detail page with only minor formatting/layout adjustments and no changes to core content such as study arms, eligibility criteria, outcomes, or listed locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check14 days agoNo Change Detected
- Check36 days agoChange DetectedMajor update: version bumped to v3.2.0 with a critical operating-status notice; previous version tag v3.1.0 removed.SummaryDifference1.0%

- Check43 days agoChange DetectedUpdated the page revision from v3.0.2 to v3.1.0, indicating a new software release or update a Ubuntu-style versioning tag.SummaryDifference0.0%

- Check58 days agoChange DetectedRevision updated from v3.0.1 to v3.0.2; the Back to Top element was removed. No other substantive content changes detected.SummaryDifference0.1%

- Check65 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. Additionally, a 'Back to Top' feature has been added for improved navigation.SummaryDifference0.1%

- Check72 days agoChange DetectedThe web page has undergone significant updates, including the addition of new facility names and locations, as well as drug information for Isatuximab and Dexamethasone. Notably, the previous version's details about various locations and drug classifications have been removed.SummaryDifference2%

Stay in the know with updates to Anti-CD38 Antibody Trial in CD38+ Malignancies
Enter your email address, and we'll notify you when there's something new on the Anti-CD38 Antibody Trial in CD38+ Malignancies page.